Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP1A1 | P05023 | 3/20 | 0.55 |
| ▸ | ATP1B1 | P05026 | 3/20 | 0.55 |
| ▸ | ATP1A3 | P13637 | 3/20 | 0.55 |
| ▸ | ATP1B2 | P14415 | 3/20 | 0.55 |
| ▸ | ATP1A2 | P50993 | 3/20 | 0.55 |
| ▸ | ATP1B3 | P54709 | 3/20 | 0.55 |
| ▸ | FXYD2 | P54710 | 3/20 | 0.55 |
| ▸ | ATP1A4 | Q13733 | 3/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.42 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | ZFP91 | Q96JP5 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 9/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL167358 | 1.00 | ATP1A1 (0.55) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL165861 | 0.99 | ATP1A1 (0.55) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL716331 | 0.99 | ATP1A1 (0.55) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL716650 | 0.96 | ATP1A1 (0.51) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL716649 | 0.96 | ATP1A1 (0.51) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL715404 | 0.94 | ATP1A1 (0.50) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL715405 | 0.94 | ATP1A1 (0.50) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL716243 | 0.94 | ATP1A1 (0.54) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL714037 | 0.94 | ATP1A1 (0.58) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL716242 | 0.94 | ATP1A1 (0.54) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9018197-B2 | Tetradecahydro-1H-cyclopenta[a]phenanthrene compounds, compositions, and related methods of use | SUZHOU NEUPHARMA CO. LTD. (CN) | 2015-04-28 | — | — | US | claimed |
| WO-2012027957-A1 | BUFALIN DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | SUZHOU NEUPHARMA CO., LTD. (CN) | 2012-03-08 | — | — | WO | claimed |
| US-20120053162-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | SUZHOU NEUPHARMA CO. LTD. (CN) | 2012-03-01 | — | — | US | claimed |
| US-9018197-B2 | Tetradecahydro-1H-cyclopenta[a]phenanthrene compounds, compositions, and related methods of use | SUZHOU NEUPHARMA CO. LTD. (CN) | 2015-04-28 | — | — | US | disclosed |
| US-20120053162-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | SUZHOU NEUPHARMA CO. LTD. (CN) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053162-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | UGT2B7, BCCIP, ABCG2 | ATP1A1 1503/4885ATP1B1 625/4885ATP1A3 2039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.